We are live on ! Find out more
JB

Julian Baker Baker Bros. Advisors

AUM $20B
1-Year Est. Return 154.41%
 

Julian Baker is co-managing member of Baker Bros. Advisors, a firm renowned for deep specialization in biotechnology and life sciences. The firm is known for concentrated positions, long holding periods, and scientific diligence that goes well beyond typical generalist research. Baker Bros. filings are closely watched by healthcare investors for signals in clinical-stage and commercial biotech.

This Fund
S&P 500
This Quarter Est. Return
-4.33%
1 Year Est. Return
+154.41%
3 Year Est. Return
+448.58%
5 Year Est. Return
+670.61%
10 Year Est. Return
+4,743.65%
AUM
$11.5B
AUM Growth
-$794M
Cap. Flow
+$217M
Cap. Flow %
1.89%
Top 10 Hldgs %
81.68%
Holding
128
New
8
Increased
22
Reduced
12
Closed
5

Top Buys

Rank Stock Value
1
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$146M
2
ABLX
Ablynx NV
ABLX
+$94M
3
PHXM
PHAXIAM Therapeutics S.A.. American Depositary Shares
PHXM
+$73M
4
RYTM icon
Rhythm Pharmaceuticals
RYTM
+$54.2M
5
ACAD icon
Acadia Pharmaceuticals
ACAD
+$45M

Top Sells

Rank Stock Value
1
AAAP
Advanced Accelerator Applications S.A.
AAAP
+$170M
2
AKAO
Achaogen Inc
AKAO
+$47.2M
3
NDRM
NeuroDerm Ltd. Ordinary Shares
NDRM
+$22.2M
4
EXEL icon
Exelixis
EXEL
+$15.3M
5
LOXO
Loxo Oncology, Inc
LOXO
+$8.85M

Sector Composition

Rank Sector Weight
1 Healthcare 99.01%
2 Technology 0.01%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
EXEL icon
26
Exelixis
EXEL
$13.4B
$45.8M 0.4%
1,506,499
-575,513
-28% -$15.3M
BLCM
27
DELISTED
Bellicum Pharmaceuticals, Inc.
BLCM
$42.3M 0.37%
503,231
– –
ACGN
28
DELISTED
Aceragen Inc
ACGN
$38.6M 0.34%
134,810
+58,949
+78% +$16.8M
RXDX
29
DELISTED
Ignyta, Inc.
RXDX
$37M 0.32%
1,384,266
+85,067
+7% +$1.38M
BLUE
30
DELISTED
bluebird bio
BLUE
$35.6M 0.31%
15,440
-3,199
-17% -$6.49M
SGMO
31
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
$34.7M 0.3%
2,113,376
– –
CERS icon
32
Cerus
CERS
$566M
$32.9M 0.29%
9,745,209
– –
HALO icon
33
Halozyme
HALO
$12.3B
$32M 0.28%
1,581,424
– –
ABEO icon
34
Abeona Therapeutics
ABEO
$348M
$31.5M 0.27%
79,375
+12,000
+18% +$4.96M
GWPH
35
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
$29.3M 0.25%
221,800
+146,800
+196% +$17.2M
CBAY
36
DELISTED
Cymabay Therapeutics
CBAY
$27.5M 0.24%
2,991,775
– –
AIMT
37
DELISTED
Aimmune Therapeutics
AIMT
$25.5M 0.22%
673,908
– –
LKFT
38
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.89B
$24.4M 0.21%
259,894
– –
CPRX
39
DELISTED
Catalyst Pharmaceutical
CPRX
$22.9M 0.2%
5,852,153
+750,000
+15% +$2.48M
MRUS
40
DELISTED
Merus
MRUS
$22.5M 0.2%
1,160,014
– –
NTLA icon
41
Intellia Therapeutics
NTLA
$1.8B
$22M 0.19%
1,145,453
+83,333
+8% +$1.92M
INSM icon
42
Insmed
INSM
$27.5B
$21.8M 0.19%
700,000
– –
XNCR icon
43
Xencor
XNCR
$2.07B
$19.1M 0.17%
872,072
– –
PGNX
44
DELISTED
Progenics Pharmaceuticals Inc
PGNX
$18.7M 0.16%
3,150,808
– –
ANAB icon
45
AnaptysBio
ANAB
$1.71B
$18.3M 0.16%
181,386
+70,000
+63% +$5.15M
AERI
46
DELISTED
Aerie Pharmaceuticals
AERI
$17.9M 0.16%
299,356
– –
IMGN
47
DELISTED
Immunogen Inc
IMGN
$16.4M 0.14%
2,563,489
-125,000
-5% -$771K
MYOK
48
DELISTED
MyoKardia, Inc. Common Stock
MYOK
$15M 0.13%
355,264
– –
FOMX
49
DELISTED
Foamix Pharmaceuticals Ltd. Ordinary Shares
FOMX
$14.8M 0.13%
2,466,702
– –
ASMB icon
50
Assembly Biosciences
ASMB
$700M
$14.6M 0.13%
26,894
+6,061
+29% +$2.74M
1
2
3 4 5

Similar funds

ASRS
Arizona State Retirement System Phoenix, Arizona $19.9B AUM 44.71% 1-Year Est. Return
FWIA
Fort Washington Investment Advisors Cincinnati, Ohio $19.9B AUM 22.19% 1-Year Est. Return
CWP
Capital Wealth Planning Naples, Florida $20B AUM 25.34% 1-Year Est. Return
SFA
Sequoia Financial Advisors Akron, Ohio $20.1B AUM 24.77% 1-Year Est. Return
MGP
M&G plc London, United Kingdom $20.1B AUM 16.62% 1-Year Est. Return
JAM
Jupiter Asset Management London, United Kingdom $20.2B AUM 29.18% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $19.7B AUM 39.39% 1-Year Est. Return
Select Equity Group
Select Equity Group New York $20.2B AUM 17.52% 1-Year Est. Return

Julian Baker's Q4 2017 Portfolio in Review

As of Q4 2017, Julian Baker held 128 positions worth $11.5B, down 6.4% from $12.3B the previous quarter. Its ten largest holdings account for 82% of the portfolio.

Julian Baker's Q4 2017 filing shows 8 new, 22 increased, 12 reduced and 5 closed positions. Its largest new stake was Ablynx NV: 4,161,118 shares worth $104M. The largest sale was Advanced Accelerator Applications S.A., an estimated $170M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, down from 99% a quarter earlier, followed by Technology.

  • Julian Baker's largest Q4 2017 buy was Ablynx NV: 4,161,118 shares worth $104M.
  • Julian Baker added most to BioMarin Pharmaceuticals in Q4 2017, an estimated $146M increase.
  • Julian Baker's biggest Q4 2017 reduction was Advanced Accelerator Applications S.A., cutting an estimated $170M.
  • Julian Baker fully exited NeuroDerm Ltd. Ordinary Shares in Q4 2017, selling an estimated $22.2M.
  • Julian Baker's ten largest holdings make up 82% of its $11.5B portfolio in Q4 2017.
  • Julian Baker opened 8 new positions and closed 5 in Q4 2017.
  • Julian Baker's portfolio value fell 6.4% quarter-over-quarter to $11.5B.

Based on Baker Bros. Advisors's 13F filing for Q4 2017, filed 14 Feb 2018.